標(biāo)題: Titlebook: Diagnosis and Management of Myelodysplastic Syndromes; A Clinical Guide Aziz Nazha Book 2020 Springer Nature Switzerland AG 2020 HSCT.CHIP. [打印本頁] 作者: TOUT 時間: 2025-3-21 16:07
書目名稱Diagnosis and Management of Myelodysplastic Syndromes影響因子(影響力)
書目名稱Diagnosis and Management of Myelodysplastic Syndromes影響因子(影響力)學(xué)科排名
書目名稱Diagnosis and Management of Myelodysplastic Syndromes網(wǎng)絡(luò)公開度
書目名稱Diagnosis and Management of Myelodysplastic Syndromes網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Diagnosis and Management of Myelodysplastic Syndromes被引頻次
書目名稱Diagnosis and Management of Myelodysplastic Syndromes被引頻次學(xué)科排名
書目名稱Diagnosis and Management of Myelodysplastic Syndromes年度引用
書目名稱Diagnosis and Management of Myelodysplastic Syndromes年度引用學(xué)科排名
書目名稱Diagnosis and Management of Myelodysplastic Syndromes讀者反饋
書目名稱Diagnosis and Management of Myelodysplastic Syndromes讀者反饋學(xué)科排名
作者: Peculate 時間: 2025-3-21 22:01 作者: Digest 時間: 2025-3-22 03:11 作者: synchronous 時間: 2025-3-22 06:01 作者: Creditee 時間: 2025-3-22 08:43 作者: CLAM 時間: 2025-3-22 13:03
MDS Mimics Including CHIP, ICUS, and CCUSns or findings of low specificity. There exist several MDS “mimics” that share findings with MDS but are caused by more benign conditions, other neoplasms, or less well-characterized pre-malignant states. Vitamin and iron deficiencies need to be excluded along with autoimmune conditions, medication 作者: CLAM 時間: 2025-3-22 20:39
Prognostic Models in Myelodysplastic Syndromestools that take both patient (e.g., age, comorbidities) and disease characteristics (e.g., blast percentage, degree of cytopenias) into account have been developed and are the basis of clinical trial enrollment, patient counseling, and treatment recommendations. Among these clinical-pathologic scori作者: 咽下 時間: 2025-3-22 22:57
Treatment Algorithms for Lower-Risk Myelodysplastic Syndromeerized by a low risk of progression to AML, but often prominent anemia. Prognosis of those patients can however be worsened by the presence of myelofibrosis, somatic mutations (except SF3B1 and TET2), resistance to first- and second-line treatments, and comorbidities..Anemia is generally the predomi作者: DEAF 時間: 2025-3-23 03:23
Treatment Algorithms for Higher-Risk Diseasel care. While hypomethylating agents (HMAs) have proven clinical and survival benefit in these patients, the only curative treatment remains allogeneic hematopoietic stem cell transplant (HSCT). No regimen has clear superiority in relapsed or refractory higher-risk MDS, and clinical trials (particul作者: 敲竹杠 時間: 2025-3-23 07:12 作者: 按等級 時間: 2025-3-23 11:46 作者: BANAL 時間: 2025-3-23 17:37
Happiness, Technology and Innovationarly those incorporating molecular data to guide biologic rationale) are of great importance to expanding treatment options for this population. Irrespective of the treatment regimen chosen, proactive supportive care is an essential component of managing these patients.作者: concert 時間: 2025-3-23 21:35
MDS Stem Cell Biologyectively eliminate these cells lie at the heart of current MDS research. Here, we highlight recent work advancing our understanding of MDS stem cell biology, with a focus on energy metabolism, inflammation, and the bone marrow niche.作者: SCORE 時間: 2025-3-23 23:46
Treatment Algorithms for Higher-Risk Diseasearly those incorporating molecular data to guide biologic rationale) are of great importance to expanding treatment options for this population. Irrespective of the treatment regimen chosen, proactive supportive care is an essential component of managing these patients.作者: instulate 時間: 2025-3-24 05:56
Book 2020The diagnosis of MDS can be challenging, while the outcomes of MDS patients vary widely. This book provides a concise yet comprehensive overview of MDS..The book begins by reviewing the diagnostic workup of MDS, with a specific focus on the 2016 WHO criteria for MDS diagnosis, and the biology and pa作者: 品牌 時間: 2025-3-24 07:09 作者: 虛弱的神經(jīng) 時間: 2025-3-24 11:47
Jonathan Gruber,Sendhil Mullainathanetry, there has been improvement in the detection of abnormal patterns and aberrant expression of antigens on all lineages in MDS. Karyotyping provides both diagnostic and prognostic information. Most recently, next generation sequencing has shed light on the molecular pathogenesis of MDS and helped in prognosticating the disease.作者: 逃避系列單詞 時間: 2025-3-24 17:46 作者: Apraxia 時間: 2025-3-24 19:14
Job Collapse on the?Way to New Athensthermore, the greater availability of genetic testing and the growing body of evidence on the prognostic relevance of somatic mutations in MDS is not captured by any standard clinical-pathologic scoring system. The ongoing efforts to develop combined clinical-pathologic-genetic risk stratification tools are reviewed herein as well.作者: EVADE 時間: 2025-3-25 02:43 作者: Innovative 時間: 2025-3-25 03:50
Morphological, Flow Cytometry, and Cytogenetic Diagnosis of MDSetry, there has been improvement in the detection of abnormal patterns and aberrant expression of antigens on all lineages in MDS. Karyotyping provides both diagnostic and prognostic information. Most recently, next generation sequencing has shed light on the molecular pathogenesis of MDS and helped in prognosticating the disease.作者: 刪除 時間: 2025-3-25 09:43 作者: Prophylaxis 時間: 2025-3-25 15:17 作者: 暴發(fā)戶 時間: 2025-3-25 19:21
Hematopoietic Cell Transplantation for MDS Patientsens have extended the indication for HCT to patients with comorbidities or reduced fitness. Less toxic but intensive regimens prior HCT and further prophylactic strategies to prevent relapse are currently under clinical investigation.作者: 沖突 時間: 2025-3-25 23:08
https://doi.org/10.1007/978-3-030-51878-3HSCT; CHIP; CCUS; ICUS; azacitidine; decitabine; lenalidomide作者: deriver 時間: 2025-3-26 02:09 作者: refraction 時間: 2025-3-26 04:40
Aziz NazhaPresented in a concise, easy-to-read format.Features over 100 illustrations, photographs, and tables.Written by experts in the field作者: 開始從未 時間: 2025-3-26 10:06 作者: pacifist 時間: 2025-3-26 16:33 作者: CLOUT 時間: 2025-3-26 19:53
Jonathan Gruber,Sendhil Mullainathaneased blasts in some cases. They can be some?of the most difficult diagnoses to make?in both developed and developing countries. MDS is?suspected by hemato-oncologists in the differential diagnosis of many cytopenic presentations?and overlaps?with many benign and malignant conditions. While the prim作者: AMBI 時間: 2025-3-26 21:00
“The ‘Three Happinesses’ and Public Policy”ultiple morphological subtypes, MDS with deletion of chromosome 5q (del(5q)) is of particular interest because of its distinct hematologic phenotype and exceptional therapeutic sensitivity to lenalidomide. Instead of homozygous inactivation, haploinsufficiency is sufficient to account for much of th作者: 愛哭 時間: 2025-3-27 02:46 作者: PATHY 時間: 2025-3-27 09:05
Job Collapse on the?Way to New Athensrver dependent and may also be associated with other hematological neoplasms or benign and reactive conditions. Although cytogenetics can provide complementary information of great importance for diagnosis and prognosis, only ~50% of de novo MDS cases carry a cytogenetic aberration. Within the last 作者: collateral 時間: 2025-3-27 10:07 作者: 北極熊 時間: 2025-3-27 15:29 作者: 珠寶 時間: 2025-3-27 21:07
Does Innovation Bring Well-being?erized by a low risk of progression to AML, but often prominent anemia. Prognosis of those patients can however be worsened by the presence of myelofibrosis, somatic mutations (except SF3B1 and TET2), resistance to first- and second-line treatments, and comorbidities..Anemia is generally the predomi作者: 整潔漂亮 時間: 2025-3-27 21:57
Happiness, Technology and Innovationl care. While hypomethylating agents (HMAs) have proven clinical and survival benefit in these patients, the only curative treatment remains allogeneic hematopoietic stem cell transplant (HSCT). No regimen has clear superiority in relapsed or refractory higher-risk MDS, and clinical trials (particul作者: HUSH 時間: 2025-3-28 02:40
https://doi.org/10.1007/978-3-030-82685-7ntial curative therapy for MDS patients, but the decision for the right candidates and the optimal moment for transplant is still a challenge. The clinical basis to recommend MDS patients for transplantation besides considering only disease-specific factors is currently provided by IPSS. Fit patient作者: 青少年 時間: 2025-3-28 07:25 作者: jet-lag 時間: 2025-3-28 11:07 作者: precede 時間: 2025-3-28 18:30
“The ‘Three Happinesses’ and Public Policy”mide in del(5q) MDS patients, some never achieve response while others develop resistance. Understanding the biology and pathophysiology of del(5q) MDS provides the basis for future therapeutic development.作者: 災(zāi)禍 時間: 2025-3-28 22:03
